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Abstract
Background Evidence is lacking for cognitive enhancer
therapy in patients with Alzheimer’s disease (AD) and
concomitant cerebrovascular disease (mixed AD) as such
patients would have been excluded from clinical trials.
Earlier studies of mixed AD have focused on large vessel
cerebrovascular disease. The influence of small vessel
cerebrovascular disease (svCVD) in the form of white
matter hyperintensity (WMH) on treatment outcomes in
mixed AD has not been addressed.
Objective In this long-term naturalistic study, we evalu-
ated the effectiveness of cognitive enhancers in patients
with mixed AD with svCVD.
Methods We conducted a retrospective analysis of a
prospective clinical database from a memory clinic of a
tertiary hospital. Magnetic resonance imaging WMH was
used as a marker of svCVD. Demographic, cognitive, and
treatment data were analysed. Linear mixed models with
patient-specific random effects were used to evaluate
cognitive outcomes over time while adjusting for
confounders.
Results Patients with mixed AD (n = 137) or AD without
svCVD (pure AD) (n = 28) were studied over a median
duration of 28.7 months. Patients with mixed AD had a
higher prevalence of hypertension (62.8 vs. 35.7 %,
p = 0.011). The majority (75.2 %) of the study sample were
managed with monotherapy. Mini Mental State Examination
(MMSE) scores decreased over time (-0.04, p = 0.007),
and the decrease was similar for both diagnosis groups (-
0.03, p = 0.246). Annual estimated mean MMSE decline
was 0.84 for pure AD and 0.48 for mixed AD. Similar trends
were observed with Montreal Cognitive Assessment
(MoCA) scores, with annual estimated mean reduction of
0.72 and 0.48 for pure AD and mixed AD, respectively.
Conclusion Cognitive enhancers are effective in slowing
the rate of cognitive decline in patients with AD with
svCVD. These findings would need to be confirmed in
randomized clinical trials.
Key Points
Cognitive enhancers demonstrate long-term benefit
in the treatment of mixed Alzheimer’s disease (AD)
and cerebrovascular disease
Among cerebrovascular diseases, the small vessel
subtype may demonstrate greater benefit with
cognitive enhancers
Randomized clinical trials of AD patients with small
vessel cerebrovascular disease are urgently needed in
view of the high prevalence of small vessel
cerebrovascular disease in AD
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1 Introduction
Alzheimer’s disease (AD) is a major cause of dementia,
with a global prevalence of 3.9 % in people older than
60 years [1]. The failure of anti-amyloid clinical trials
necessitates exploration of other biological factors that can
potentially delay the onset and progression of AD [2].
Cerebrovascular disease can modify the clinical expression
and treatment response in AD [3].
Small vessel cerebrovascular disease (svCVD) is pre-
valent among patients with AD, resulting in mixed AD [4,
5]. On neuroimaging, AD patients with svCVD will dem-
onstrate white matter hyperintensity (WMH) and lacunes
[6]. WMH has been strongly associated with other markers
of vascular disease [7, 8], greater cognitive impairment in
AD, and higher risk of progression from mild cognitive
impairment to AD [9–11]. The Honolulu-Asia Aging Study
has demonstrated the role of co-prevalent brain lesions
such as amyloid pathology, brain atrophy, and microvas-
cular infarcts in AD, hence the importance of recognizing
and treating patients with AD and svCVD [12].
Cholinergic dysfunction is well recognized in AD, and
acetylcholinesterase inhibitors have shown benefit on cog-
nitive and functional outcomes in AD [13–16]. Similarly,
WMH has been shown to impair cholinergic function in the
brain [17]. The combined effect of AD pathology and WMH
on cerebral cholinergic function is likely to be greater than
the individual effects of each of the two pathologies [18]. We
thus postulate that AD patients with svCVD (mixed AD) will
demonstrate greater cognitive benefit with cognitive
enhancers. In this study, we compared the effectiveness of
cognitive enhancers between AD patients with and without
svCVD in a real-world tertiary clinic setting.
2 Methods
2.1 Study Design and Study Sample
The study was a retrospective review of a prospective
electronic clinical database of dementia patients with data
on diagnosis, treatment, follow-up (monitoring), and cog-
nitive and functional outcomes. The study was approved by
the Institutional Review Board.
The study sample included outpatients from a tertiary
dementia clinic, who were enrolled between January 2006
and July 2013. Sociodemographic, clinical (including use
of cognitive enhancers), and outcome information on these
patients were recorded on our medical electronic database.
We focused primarily on cognitive outcomes, and consid-
ered the cognitive enhancers acetylcholinesterase inhibitors
and N-methyl-D aspartate (NMDA) antagonists.
We queried the database for all dementia outpatients
who satisfied the following inclusion criteria: diagnosis of
mild to moderate AD based on Diagnostic and Statistical
Manual of Mental Disorders, fourth edition, text revision
(DSM-IV TR) criteria [19], clinical dementia rating (CDR)
of 1–2 [20], availability of neuroimaging data and Mini-
Mental State Examination (MMSE) score [21], and treat-
ment with cognitive enhancers for at least 6 months.
Patients who had a break in the use of cognitive enhancers
for more than 3 months were excluded from the study.
Of 951 dementia patients seen from January 2006 to
July 2013, a total of 165 eligible patients were identified.
Of these, 137 (83 %) patients had mixed AD
(AD ? svCVD) and 28 (17 %) patients had AD without
svCVD (pure AD) (Fig. 1).
2.2 Measurements
AD was diagnosed based on the DSM-IV TR criteria. The
presence of WMH on brain magnetic resonance imaging
(MRI) was used as a surrogate marker for svCVD. WMH
were semi-quantitatively rated using the modified-Fazekas
scale on T2-weighted MRI images by an experienced cli-
nician [22]. Periventricular WMH (pv-WMH) was graded
as 0 = absence, 1 = ‘caps’ or thin lining, 2 = ‘halo’, and
3 = irregular pv-WMH extending into the white matter.
Deep subcortical WMH (dsc-WMH) was rated as
0 = absence, 1 = punctuate foci, 2 = confluent foci and
3 = large confluent areas. Total score was obtained by the
summation of pv-WMH and dsc-WMH in the right and left
hemispheres for a total score of 12. AD patients with a total
WMH score of C6 points were classified as mixed AD, and
pure AD otherwise.
Patients were receiving either donepezil (5–10 mg/day),
rivastigmine (oral 3–12 mg/day or patch 4.6–9.8 mg/day),
galantamine (8–24 mg/day), or memantine (10–20 mg/
day), or a combination of these cognitive enhancers.
Cognitive outcomes were routinely assessed during each
clinic visit using the MMSE, Montreal Cognitive Assess-
ment (MoCA), and Geriatric Depression Scale (GDS) [23,
24]. MMSE and MoCA were used as the primary outcomes
of this study. These endpoints were used to estimate the
severity of cognitive impairment at ‘baseline’ and to follow
the course of cognitive changes over time. We defined
‘baseline’ as the first time a patient was diagnosed or
assessed at our institution.
2.3 Statistical Methods
Summary tables were used to describe the frequency and
proportion of patients, as well as mean or median of so-
ciodemographic and clinical characteristics and outcomes,
by diagnostic groups (mixed AD and pure AD). Line plots
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were used to depict the evolution of outcomes over time, at
the patient level and the diagnostic group level. The two-
sample t-test and Kruskal–Wallis test were used to com-
pare means and medians, respectively, of continuous
variables between diagnosis groups. Fisher’s exact test was
used to test associations between categorical variables and
diagnosis groups.
Linear mixed models (LMM) with patient-specific ran-
dom effects were used to evaluate the evolution of the
outcomes over time while accommodating the dependence
in the data, due to repeated assessments of each patient
over time; identifying and adjusting for potential con-
founders; and accounting for missingness in the data [25–
27]. Results from LMM were valid under the missing at
random missingness assumption, which implied that, con-
ditional on the observed data, the missingness was inde-
pendent of the unobserved assessments [28, 29]. Patient-
specific random effects and an unstructured (general) var-
iance-covariance matrix were used to account for the dif-
ferences in number of assessments as well as duration
between assessments, between patients.
First, a ‘base-model’ was developed based on diagnosis
group, follow-up time, and patient-specific random effects
only. Second, each sociodemographic and clinical charac-
teristic was added separately to the base model in order to
identify potential confounders. We henceforth refer to such
models as univariable models. Third, a final model was
developed by adding all potential confounders simulta-
neously to the base model, henceforth referred to as mul-
tivariable models. Medication was considered as a time
varying covariate in the univariable and multivariable
models. Appropriate mixture of Chi-squared tests were
used to test the variances of the patient-specific random
effects [26, 27].
The significance level was set at 5 % and all tests were
two-sided. SAS version 9.2 software (SAS Institute, Cary,
NC, USA) was used for the analyses.
3 Results
3.1 Baseline Characteristics
A total of 165 patients (137 [83 %] mixed AD patients and
28 [17 %] pure AD patients), met the study eligibility
criteria, of whom 140 (84.8 %) were Chinese and 70
(42.4 %) were male. At baseline, the median age was
73 years; the median years of education was 6 years; the
prevalence of diabetes, hypertension, and hyperlipidemia
was 26.1, 58.2 and 57.9 %, respectively; the mean GDS
score was 3.1 (standard deviation [SD] 3.2); the mean
MMSE score was 20.6 (SD 5.4); and the mean MoCA
score was 20.9 (SD 5.0). The mean WMH in the pure AD
group was 1.8 (SD 3) and that for AD ? svCVD was 8.1
(SD 3.4).
Table 1 summarizes the baseline characteristics by
diagnosis group. Compared with patients with mixed AD,
patients with pure AD were younger (8 years, p = 0.001),
had more years of education (3 years, p = 0.019), and had
a lower prevalence of hypertension (27.1, p = 0.011).
Patients with mixed AD performed significantly worse
(20.1 vs. 23.0, p = 0.007) on the MMSE. The mixed AD
group had lower baseline scores on the MoCA, but this was
not statistically different (20.5 vs. 22.5, p = 0.142).
3.2 Follow-up Characteristics
Patient management (treatment, monitoring, and assess-
ment) was reviewed, and adjusted if necessary, routinely
within 4–6 months of the previous clinic visit. The rela-
tionship between duration of follow-up and number of
assessments was influenced by our practice as well as
patient compliance with their clinic appointments. Conse-
quently, the number of assessments and the duration
between repeated assessments within patients were not
fixed.
Fig. 1 Flow diagram of eligible
patient selection. MMSE Mini-
Mental State Examination, MRI
magnetic resonance imaging
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The median duration of follow-up of the eligible sample
was 28.7 months (range 5–85). The duration of follow-up
in the mixed AD group (median 28.2 months; range 5–85)
was not significantly different to that of the pure AD group
(median 36.0 months; range 8–82), although it was slightly
longer for the pure AD group on average. The median
number of assessments per patient was six (range 2–10)
and was slightly higher, on average, for the pure AD group,
possibly owing to the slightly longer follow-up (Table 1).
3.3 Use of Cognitive Enhancers
Overall, i.e. based on the number of patients who received
any of the cognitive enhancers considered at least once, the
most commonly used cognitive enhancer was rivastigmine
in patch or oral form (57.6 %), followed by donepezil
(37.0 %), memantine (20.0 %), and galantamine (13.3 %).
Rivastigmine was the most prescribed first-line treatment,
whereas galantamine and memantine were the most
Table 1 Demographic, baseline clinical, and follow-up characteristics
Characteristic Mixed AD (AD ? svCVD) [137 (83 %)] Pure AD [28 (17 %)] p value
Demographics
Age (years)
Mean (SD) 73.4 (8.00) 67.2 (8.83) 0.0014a
Median (min, max) 74.0 (54, 91) 66.0 (46, 80) 0.0013b
Male, n (%) 54 (39.4) 16 (57.1) 0.0960c
Race, n (%)
Chinese 119 (86.9) 21 (75.0) 0.1449c,d
Malay 5 (3.6) 2 (7.1)
Indian 5 (3.6) 3 (10.7)
Others 8 (5.8) 2 (7.1)
Years of education
Mean (SD) 5.8 (4.69) 8.1 (4.48) 0.0222a
Median (min, max) 6.0 (0, 17) 9.0 (0, 16) 0.0191b
Baseline clinical characteristics
Diabetes mellitus, n (%) 37 (27.0) 6 (21.4) 0.6413c
Hypertension, n (%) 86 (62.8) 10 (35.7) 0.0112c
Hyperlipidemia, n (%) 82 (60.3) 13 (46.4) 0.2093c
MMSE (n = 165)
Mean (SD) 20.1 (5.43) 23.0 (4.77) 0.0066a
Median (min, max) 20.0 (11, 30) 24.5 (12, 29) 0.0106b
MoCA (n = 87)
Mean (SD) 20.5 (4.98) 22.5 (4.72) 0.1417a
Median (min, max) 21.0 (7, 30) 24.0 (12, 30) 0.1207b
GDS (n = 68)
Mean (SD) 3.2 (3.35) 2.0 (1.73) 0.1082a
Median (min, max) 2.0 (0, 15) 2.0 (0, 5) 0.4720b
Follow-up characteristics
Duration of follow-up (months)
Mean (SD) 31.1 (17.56) 37.0 (19.46) 0.1424a
Median (min, max) 28.2 (6, 85) 36.0 (8, 82) 0.1097b
Number of assessments/visits
Mean (SD) 6.1 (2.59) 7.1 (3.01) 0.1154a
Median (min, max) 6.0 (2, 10) 8.0 (2, 10) 0.0836b
AD Alzheimer’s disease, GDS Geriatric Depression Scale, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment,
svCVD small vessel cerebrovascular disease, SD standard deviation
a p value based on two-sample t-test with unequal variance
b p value based on Wilcoxon rank sum (Kruskal–Wallis) test
c p value based on Fisher’s Exact Test
d p value calculated using dichotomized variable (Chinese: Yes | No)
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prescribed second-line treatments. The same pattern of
prescription was observed for both mixed AD and pure AD
groups.
The majority (75.2 %) of the study sample were man-
aged based on monotherapy with a cognitive enhancer,
while the cognitive enhancer for some patients was swit-
ched once (21.8 %) or twice (3.0 %). The median time to
the first switch of cognitive enhancers, mostly due to
intolerance or side effects, was 4.8 months (range 0.5–30).
Patients with mixed AD had a slightly longer median time
to first switch (5.2 months [range 1–30]) than patients with
pure AD (3.0 months [range 0.5–7]) (Table 2).
3.4 Outcomes
Loess line plots of MMSE and MoCA scores over time by
diagnosis groups indicated the plausibility of an average
linear profile over time (Fig. 2b, d). Similarly, patient level
loess line plots of MMSE and MoCA scores over time
indicated an approximate linear profile over time (Fig. 2a,
c). Thus a base model was specified with the following
fixed effects: of diagnosis group (pure AD) with mixed AD
as the reference group, follow-up duration (FDur), inter-
action between diagnosis group and duration of follow-up
(pure AD 9 FDur). The random effects consisted of
patient-specific intercepts and slopes as well as a residual
variance. The variance of the random intercept, D(1,1),
represented the degree of variability of patients’ cognitive
impairment at baseline, while the variance of the random
slope, D(2,2), indicated whether response to management
over time was similar (small) or variable (large) between
patients. The covariance (correlation) between the patient-
specific intercept and slope indicated whether the evolution
of patients’ cognitive impairment over time was related to
their condition at baseline. Higher order (quadratic and
cubic) models were considered at both the fixed- and ran-
dom-effects level and Akaike’s information criteria (AIC)
indicated that the linear model was acceptable (Table 3)
[30].
‘Years of education’ was the only confounder with
significance on the MMSE, as well as the MoCA scores.
Based on MMSE, pure AD patients seemed to be less
cognitively impaired at baseline (2.36, p = 0.023), but this
difference was not significant in the multivariable analysis
after adjusting for years of education (1.48, p = 0.156).
There was a slight decrease in MMSE scores over time (-
0.04, p = 0.007), and the decrease over time was similar
for both diagnosis groups (-0.03, p = 0.246). The annual
estimated mean reduction of MMSE score was less than 1
for both the pure AD (0.84) and the mixed AD (0.48)
groups. Similar trends were observed based on the MoCA
scores, with annual estimated mean reduction of 0.72 and
0.48 for pure AD and mixed AD groups, respectively
(Table 3).
For both MMSE and MoCA scores, the variance of the
patient-specific intercept was ‘large’ ([20), indicating that
the severity of cognitive impairment at baseline varied
substantially from patient to patient. This was expected in
data obtained from clinical practice, unlike randomized
controlled trial data. The small variances of the patient-
specific slopes indicated that the reduction in cognition
over time was similar from patient to patient, and the
Table 2 Cognitive enhancers and treatment characteristics
Characteristic AD ? svCVD [137 (83 %)] Pure AD [28 (17 %)] Total [165 (100 %)]
Treatment characteristics p value
Number of treatments per patient, n (%)
1 101 (73.7) 23 (82.1) 0. 4730a,b
2 31 (22.6) 5 (17.9)
3 5 (3.6) 0 (0.0)
Total duration of treatment (months)
Mean (SD) 29.8 (17.98) 31.4 (22.88) 0.7228c
Median (min, max) 27.7 (4, 85) 31.3 (3, 82) 0.9931d
Duration of first-line treatment for patients with more than 1 treatment
n 36 5
Mean (SD) 9.0 (8.14) 3.8 (2.53) –
Median (min, max) 5.2 (1, 30) 3.0 (0.5, 7) 0.1404d
AD Alzheimer’s disease, SD standard deviation, svCVD small vessel cerebrovascular disease
a p value based on Fisher’s exact test
b p value calculated using dichotomized variable (one vs. more than one)
c p value based on two-sample t-test with unequal variance
d p value based on Wilcoxon rank sum (Kruskal–Wallis) test
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reduction in cognition did not depend on the severity of
cognitive impairment at baseline, as indicated by the small
covariances between the patient-specific intercepts and
slopes. These trends were similar for the base, univariable,
and multivariable models.
4 Discussion
In our study of a clinical cohort of patients with AD, we
found that cognitive enhancers are effective in slowing the
rate of cognitive decline in both patients with pure AD and
those with mixed AD. Importantly, there was a trend to
greater cognitive benefit, characterized by a slower rate of
cognitive decline in patients with mixed AD than in those
with pure AD. The results remain significant even after
adjusting for years of education and inherent variability in
the severity of cognitive decline between patients.
Both the MMSE and MoCA demonstrated a trend
towards cognitive benefit for patients with mixed AD when
treated with cognitive enhancers. MMSE and MoCA were
both validated for screening and monitoring of AD, with
the MoCA found to be a better cognitive tool than MMSE
[31]. The MoCA had also been shown to reveal higher
sensitivity to cognitive decline in longitudinal monitoring.
The MMSE and MoCA score changes showed similar
trends during the follow-up period (Fig. 2), suggesting a
robust benefit when patients with mixed AD were treated
with cognitive enhancers. As clinical trials with cognitive
enhancers in AD only include patients with probable AD,
effectively excluding AD patients with concomitant
svCVD, this real-life study from a clinic cohort for the first
time provided direct evidence for benefit when patients
with mixed AD with svCVD were treated with cognitive
enhancers.
A previous longitudinal study of AD showed that the
annual rate of cognitive decline based on MMSE scores
was 2.3 without treatment with cognitive enhancers [32]. A
review of cholinesterase inhibitors for AD showed that
MMSE mean change from baseline to 6 months ranged
Fig. 2 LOESS line plots of cognitive outcomes over time by
randomly selected patients and diagnosis groups: a patient-level
evolution of MMSE, b average evolution of MMSE by diagnosis
group, c patient-level evolution of MoCA, and d average evolution of
MoCA by diagnosis group. AD Alzheimer’s disease, MMSE Mini-
Mental State Examination, MoCA Montreal Cognitive Assessment,
svCVD small vessel cerebrovascular disease
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from -0.5 to 1.35 [33]. In this current study, we demon-
strated in a long-term real-life clinic study that, with cog-
nitive enhancers, the average annual decline in MMSE
scores was 0.84 for patients with pure AD and 0.48 for
patients with AD ? svCVD. The change of -0.84 for pure
AD is in keeping with previous literature. More impor-
tantly, we demonstrated that patients with mixed AD of the
svCVD category showed less annual cognitive decline
when treated with cognitive enhancers.
Patients with long-standing hypertension have been shown
to have increased rates of white matter lesions, both peri-
ventricular and subcortical, while hyperlipidemia had been
associated with less severe WMH [34, 35]. In our cohort,
cardiovascular risk factors were more prevalent, significantly
so for hypertension, in mixed AD patients than in pure AD
patients, which is consistent with current literature.
WMH has been associated with greater cognitive
impairment in AD [10]. The baseline MMSE scores of our
Table 3 Univariable and multivariable analyses of cognitive outcomes based on MMSE and MoCA
Models MMSE MoCA
Estimate (SD) p value Estimate (SD) p value
Base model
Intercept 20.33 (0.45) \0.0001 19.83 (0.51) \0.0001
Pure AD 2.36 (1.03) 0.0226 1.85 (1.12) 0.0999
FDur (months) -0.04 (0.01) 0.0101 -0.04 (0.02) 0.0168
PureAD 9 FDur -0.03 (0.03) 0.2160 -0.02 (0.03) 0.5409
D11 24.60 (3.07) \0.0001 21.53 (3.52) \0.0001
D12 0.12 (0.07) 0.0977 -0.02 (0.10) 0.8532
D22 0.01 (0.00) \0.0001 0.01 (0.00) 0.0042
Residual variance 5.74 (0.33) \0.0001 5.52 (0.45) \0.0001
Univariable models
Age -0.08 (0.05) 0.1227 -0.08 (0.06) 0.1318
Female -2.51 (0.80) 0.0018 -1.99 (0.85) 0.0206
Chinese -1.13 (0.99) 0.2505 0.19 (1.05) 0.8597
Years of education 0.39 (0.08) \.0001 0.21 (0.10) 0.0294
Diabetes mellitus -0.67 (0.91) 0.4606 -0.62 (1.02) 0.5426
Hypertension -0.09 (0.83) 0.9153 0.03 (0.90) 0.9720
Hyperlipidemia 0.63 (0.83) 0.4460 0.99 (0.92) 0.2847
Medicationsa Donepezil 0.06 (0.47) 0.9018 -0.27 (0.66) 0.6877
Galantamine 0.08 (0.67) 0.9096 0.93 (0.98) 0.3415
Memantine -1.58 (0.71) 0.0266 -0.88 (1.20) 0.4624
Rivastigmine – – –
Duration of treatment 0.01 (0.01) 0.4651 -0.01 (0.02) 0.5022
Baseline MoCA|MMSE 0.68 (0.05) \0.0001 0.84 (0.06) \0.0001
Baseline GDS 0.08 (0.18) 0.6693 0.03 (0.21) 0.886
Multivariable models
Intercept 18.04 (0.63) \0.0001 18.33 (0.84) \0.0001
Pure AD 1.48 (1.04) 0.1561 1.64 (1.11) 0.1396
FDur (months) -0.04 (0.01) 0.0069 -0.04 (0.02) 0.0189
Pure AD 9 FDur -0.03 (0.03) 0.2461 -0.02 (0.03) 0.5135
Years of education 0.39 (0.08) \0.0001 0.21 (0.10) 0.0294
D11 21.71 (2.75) \0.0001 20.17 (3.39) \0.0001
D12 0.18 (0.07) 0.0070 0.04 (0.10) 0.6984
D22 0.01 (0.00) 0.0002 0.01 (0.00) 0.0073
Residual variance 5.67 (0.33) \.0001 5.43 (0.44) \0.0001
AD Alzheimer’s disease, D11 and D22 variance of subject-specific intercepts and slopes, respectively, D12 covariance between subject-specific
intercepts and slopes, FDur duration of follow-up, GDS Geriatric Depression Scale, MMSE Mini-Mental State Examination, MoCA Montreal
Cognitive Assessment, SD standard deviation
a Included as time-varying variable
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patients with mixed AD were significantly lower than those
of the pure AD patients (20.1 vs. 23), although this sig-
nificance disappeared after adjusting for years of education
in the multivariable analysis. Interestingly, there were no
sharp changes in MMSE scores over the period of follow-
up, and the baseline MMSE scores did not influence the
progression of MMSE scores.
Cholinergic dysfunction has been well described in AD
[13]. In vivo imaging studies provided supportive evidence
that periventricular white matter lesions were associated
with cortical cholinergic deafferentation in elderly patients
with leukoaraiosis [17]. CVD may directly affect cholin-
ergic white matter projections and may exacerbate pre-
existing cholinergic deficits in AD [36]. The presence of
periventricular WMH is also significantly associated with
lower cortical cholinergic activity, supporting a regionally
specific disruption of cholinergic projection fibers by
WMH [37]. The cognitive benefit seen in our analysis
confirmed the presence of cholinergic dysfunction in both
patients with pure AD and those with mixed AD. The
greater cognitive benefit seen in patients with
AD ? svCVD supported our hypothesis that the combined
effect of AD pathology and WMH resulted in greater
cholinergic dysfunction.
The key strengths of our study was the length of follow-
up of our patients; the median duration of follow-up for
mixed AD and pure AD was 28.2 and 36 months, respec-
tively. Furthermore, our study was a naturalistic study on
outcomes of cognitive enhancers in AD that aimed to
describe results from treatment in patients who were trea-
ted by usual care. Naturalistic studies mirrored naturalistic
outpatient settings and so served a complementary role to
more structured efficacy trials and pragmatic studies of
AD. The study also has several limitations: this was a
retrospective study without randomization of cognitive
enhancer assignment and no control for prestudy exposure
to other medications. The results were findings from a
single center with the types of cognitive enhancers used
representing the practice in our center. However, this
practice was based on evidence of cognitive enhancers that
were shown to delay cognitive impairment in patients with
mild to moderately severe AD, with no robust support for
any one drug [14]. Patients with AD ? svCVD were over-
represented in our sample, which may reduce the gener-
alizability of our findings. Hence, these findings should be
confirmed in independent samples with adequate repre-
sentation of patients with ‘pure AD’ and ‘AD ? svCVD’.
5 Conclusion
Cholinergic dysfunction is present in both AD and mixed
AD of the svCVD category. Cognitive enhancers are
effective in slowing the rate of cognitive decline in patients
with AD, and seemingly more so for patients with mixed
AD of the svCVD category. The finding of potential benefit
of cognitive enhancer therapy for patients with
AD ? svCVD will need to be confirmed in randomized
clinical trials.
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